Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
5-fluorouracil (5-FU)
21%
95% Confidence Interval
20%
Acute Myeloid Leukemia
23%
Adult Patients
17%
Advanced Gastric Cancer
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
36%
Anthracyclines
23%
Autologous Stem Cell Transplantation (auto-SCT)
27%
Bone Marrow
22%
Bortezomib
47%
C(X)
23%
CD34+
35%
Cell-conditioned Medium
29%
Chemotherapy
57%
Chronic Myeloid Leukemia
48%
Cisplatin
31%
Combination Chemotherapy
26%
CXCR2
24%
Cyclophosphamide
36%
Cytomegalovirus Reactivation
17%
Diffuse Large B-cell Lymphoma (DLBCL)
25%
Granulocyte Colony-stimulating Factor (G-CSF)
20%
Human Embryonic Stem Cells (hESCs)
18%
Human Mesenchymal Stem Cells (hMSCs)
27%
Human Placenta
21%
Human Pluripotent Stem Cells (hPSCs)
47%
Imatinib
21%
Imatinib Mesylate
29%
Induced Pluripotent Stem Cells (iPSCs)
46%
Lens-free Shadow Imaging Technology
31%
Leucovorin
31%
Leukemia Patients
22%
Mammalian Target of Rapamycin (mTOR)
18%
Mesenchymal Stem Cells
16%
Multiple Myeloma
81%
Multiple Myeloma Patients
35%
Natural Killer Cells
16%
Neutropenia
29%
Newly Diagnosed
25%
Overall Survival
32%
Placenta Cells
28%
Platelet Count
27%
Pluripotent Stem Cell Line
40%
Prognostic Value
25%
Programmed Death-ligand 1 (PD-L1)
23%
Receptor 2
23%
Risk Factors
21%
South Korea
47%
Stem Cells
22%
Treatment Outcome
32%
Medicine and Dentistry
Abdominal Cancer
25%
Allogeneic Hematopoietic Stem Cell Transplantation
16%
Anemia
31%
Aplastic Anemia
23%
Autologous Stem Cell Transplantation
38%
Bortezomib
25%
Chemotherapy
92%
Cisplatin
41%
Cohort Analysis
16%
Combination Chemotherapy
17%
Cyclophosphamide
14%
Cytomegalovirus
23%
Diffuse Large B-Cell Lymphoma
40%
Diseases
29%
Eculizumab
15%
Epirubicin
17%
Etoposide
18%
Febrile Neutropenia
17%
Ferritin
18%
Fluorouracil
23%
Folinic Acid
31%
Hazard Ratio
16%
Hematopoietic Stem Cell Transplantation
15%
Idiopathic Thrombocytopenic Purpura
15%
Leukemia
17%
Long Term Survival
17%
Lymphocyte
22%
Malignant Neoplasm
29%
Melphalan
15%
Monotherapy
15%
Multiple Myeloma
90%
Multivariate Analysis
17%
Myelodysplastic Syndrome
31%
Myeloma
17%
Natural Killer Cell
16%
Neuropathy
22%
Neutropenia
25%
NK T Cell Lymphoma
39%
Non-Hodgkin Lymphoma
28%
Observational Study
15%
Overall Survival
69%
Paroxysmal Nocturnal Hemoglobinuria
15%
Platelet
48%
Prognostic Factor
31%
Progression Free Survival
39%
Risk Stratification
18%
Stem Cell Mobilization
15%
Survival Rate
21%
Treatment Outcome
40%
Vasculotropin
23%
Immunology and Microbiology
Acute Graft Versus Host Disease
11%
Allogeneic Hematopoietic Stem Cell Transplantation
18%
Aplastic Anemia
15%
Autologous Stem Cell Transplantation
19%
B Cell
39%
Blood Level
13%
Blood Plasma
13%
CD34
39%
Cell Culture Technique
10%
Cell Line
11%
Cyclophosphamide
27%
Cytomegalovirus
15%
Dexamethasone
15%
Dioxygen
23%
Drug Megadose
25%
Embryoid Body
12%
Exosome
15%
Feeder Cell
17%
Fibroblast
14%
Fibroblast Growth Factor 2
20%
Hematopoietic Cell
34%
Human Embryonic Stem Cell
39%
Immunoglobulin Producing Cell
27%
Immunomodulatory Drug
10%
In Vitro
15%
Induced Pluripotent Stem Cell
23%
Infection
13%
Infectious Disease
13%
Intravenous Immunoglobulin
15%
Lens
15%
Lymphocyte
22%
Mesenchymal Stem Cell
11%
Mononuclear Cell
11%
Multiple Myeloma
100%
Neutrophil
13%
Overall Survival
53%
Placenta
50%
Platelet
18%
Platelet Count
22%
Pluripotent Stem Cell
25%
Pluripotent Stem Cell Line
16%
Pretreatment
16%
Programmed Death 1 Ligand 1
39%
Programmed Death-Ligand 1
13%
Progression Free Survival
26%
Severe Acute Respiratory Syndrome Coronavirus 2
15%
Stem Cell
13%
Stem Cell Line
23%
Steroid
15%
Vasculotropin
15%